New drug targets tough lymphoma in early trial

NCT ID NCT07069699

First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 31 times

Summary

This study tests a new drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it can shrink tumors. Participants have already tried other treatments and have limited options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.